CD33CART

CD33CART is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy targeting the myeloid cell surface antigen CD33. Developed for pediatric, adolescent, and young adult patients (up to age 35) with relapsed or refractory acute myeloid leukemia (AML), the therapy involves genetically modifying a patient's own T cells to express a CAR construct specific for CD33, a protein highly expressed on AML blasts. The therapy is being evaluated in a multicenter Phase 1/2 clinical trial (NCT03971799) sponsored by the National Marrow Donor Program (NMDP) in collaboration with the Pediatric Transplantation and Cell Therapy Consortium. Manufacturing is performed using the CliniMACS Prodigy system at the Biopharmaceutical Development Program of the Frederick National Laboratory for Cancer Research. The primary therapeutic objective is to induce a complete remission, ideally minimal residual disease (MRD) negative, to serve as a bridge to a definitive allogeneic stem cell transplant.

Other names

CD33-targeting CAR T-cell therapyCD-33-targeting CAR T-cell therapyCD 33-targeting CAR T-cell therapyCD33 CAR-TCD-33 CAR-TCD 33 CAR-T